Amaryl - Warnings & Precautions
Amaryl - Warnings & Precautions
HealthCentral.com
WARNINGS
SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY
The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term, prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes, 19 supp. 2: 747-830, 1970).
UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality.
Please visit the website to view the rest of the article.
Email contact: comments@thcn.com
Corporate Headquarters
1655 N Fort Myer Drive
Suite 400
Arlington, VA 22209
Phone: 703-302-1040
Fax: 703-248-0830
Sales Headquarters
444 Park Avenue South
Suite 1102
New York, NY 10016
Phone: 212-213-9200
Fax: 212-213-9244
Broadcast Media Group Headquarters
6507 Jester Blvd.,
Building 5/Suite 510-N
Austin, TX 78750
Phone: (512) 335-3336
Copyright © 2005-2008. The HealthCentral Network, Inc. All rights reserved.
